Danaher reported lower-than-expected revenue for its biotechnology business and revised its full-year core revenue growth guidance, lowering the upper end from 6% to 4% while maintaining the lower end at 3%. Intuitive Surgical, despite strong quarterly results, did not raise its 2026 da Vinci procedure volume growth guidance, keeping it between 13.5%-15.5% and expecting results to be closer to the midpoint.